pharma · Minimal Residual Disease · Pancreatic Ductal Adenocarcinoma · ELTX
Elicio Therapeutics
Elicio Therapeutics is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker ELTX. Primary therapeutic focus areas include Minimal Residual Disease, Pancreatic Ductal Adenocarcinoma. NovaPhar
Boston, USA HQ
47 Employees
Public company Type
ELTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boston, USA
- Employees
- 47
- Programs
- 2
- Drugs
- 0
- Patents
- 4
ELI-002 7P
Phase 2 · small molecule · Pancreatic Ductal Adenocarcinoma
ELI-002 7P for Pancreatic Ductal Adenocarcinoma is a Phase 2 program (small_molecule) at Elicio Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code ELI-002-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Elicio Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Pancreatic Ductal Adenocarcinoma
- Status
- active
- Trials
- 1